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Abstract
Fibroblast growth factor receptor 4 (FGFR4) is vital in early development and tissue repair. FGFR4 expression levels are very
restricted in adult tissues, except in several solid tumors including colorectal cancer, which showed overexpression of
FGFR4. Here, FGFR4 mutation analysis discarded the presence of activating mutations, other than Arg388, in different
colorectal cancer cell lines and tumoral samples. Stable shRNA FGFR4-silencing in SW480 and SW48 cell lines resulted in a
significant decrease in cell proliferation, adhesion, cell migration and invasion. This decrease in the tumorigenic and invasive
capabilities of colorectal cancer cells was accompanied by a decrease of Snail, Twist and TGFb gene expression levels and an
increase of E-cadherin, causing a reversion to a more epithelial phenotype, in three different cell lines. In addition, FGFR4-
signaling activated the oncogenic SRC, ERK1/2 and AKT pathways in colon cancer cells and promoted an increase in cell
survival. The relevance of FGFR4 in tumor growth was supported by two different strategies. Kinase inhibitors abrogated
FGFR4-related cell growth and signaling pathways at the same extent than FGFR4-silenced cells. Specific FGFR4-targeting
using antibodies provoked a similar reduction in cell growth. Moreover, FGFR4 knock-down cells displayed a reduced
capacity for in vivo tumor formation and angiogenesis in nude mice. Collectively, our data support a crucial role for FGFR4 in
tumorigenesis, invasion and survival in colorectal cancer. In addition, FGFR4 targeting demonstrated its applicability for
colorectal cancer therapy.
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Introduction
The fibroblast growth factors (FGFs) have been implicated in
multiple biological processes during embryo development, wound
healing, haematopoiesis and angiogenesis [1]. They bind to four
FGF receptors (FGFR) designated FGFR1-4 [2]. The FGFRs
structure includes a ligand-binding domain that contains three
different immunoglobulin-like domains (called Ig I, Ig II and Ig
III). The ligand domain is followed by a single transmembrane
domain and an intracellular cytoplasmic tyrosine kinase domain.
FGFR4 displays the most restricted pattern of expression to
embryonic development and tissue repair [3,4] when compared to
the other three FGFRs, and its expression levels decline
postnatally. In adults, FGFR4 is expressed in muscle myofibro-
blasts during regeneration following injury, but not in mature
skeletal muscle [5]. FGF receptors dysregulation has been shown
to play an important role in cancer development and progression.
These alterations have been proposed to occur through overex-
pression, gene amplification or mutation [6].
Previously, our group identified FGFR4 as an autoantibody
target in colorectal cancer (CRC) using protein microarrays [7]. In
addition, we observed a clear overexpression of FGFR4 in
colorectal cancer cell lines (particularly in 2 out of 4 highly
metastatic colorectal cancer cell lines) with a potential association
of FGFR4-expression to late stages colorectal cancer [8]. FGFR4
has been reported to be over-expressed in human breast, prostate,
colon, rhabdomyosarcoma, gastric, pancreatic, hepatocellular and
pituitary adenocarcinomas [4,9,10,11,12,13,14,15], where it can
contribute to tumor progression by multiple mechanisms [4,9].
Moreover, FGFR4 expression levels were associated with meta-
static disease and poor survival in gastric, lung, breast adenocar-
cinoma and rhabdomyosarcoma [16,17,18]. FGFR4 somatic
mutations are infrequent in cancer [11,19,20,21]; Arg388 is the
most common single nucleotide polymorphism (SNP) in FGFR4,
which provokes enhanced stability and prolonged activation of the
receptor. It has been associated with poor prognosis for positive
node breast cancer, high-grade soft-tissue sarcoma, head and neck
and lung squamous cell carcinoma [9,16,18,22,23].
Among the 18 FGF ligands, FGF19 binds preferentially FGFR4
[24], although it binds also FGFR1. Binding occurs in a complex
comprising heparin, FGFR4 and two FGF molecules, which
triggers FGFR dimerization, leading to autophosphorylation of
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multiple tyrosine residues in the intracellular tyrosine kinase
domain [3,25]. FGF19-FGFR4 has been proposed to play a role in
the induction of hepatocyte proliferation and carcinogenesis [26].
Antibodies directed against FGF19 have shown therapeutic
promise in different tumor xenografts [27]. However, blocking
of FGF19 might act on different FGF receptors [28].
We have used different colon cancer samples and cell lines
(SW480, SW620, SW48, KM12C and KM12SM) [29,30,31] to
investigate the presence of SNPs or activating mutations in
FGFR4 and to characterize its biological relevance as oncogene
and therapeutic target in colorectal cancer. KM12C and
KM12SM epithelial cells possess similar genetic background,
differing in their metastatic properties [31]. SW480 and SW620
are two isogenic colorectal cancer cell lines. SW480 was isolated
from a primary Duke’s B tumor of colorectal cancer, whereas
SW620 cell line was isolated from a metastatic lymph node of the
same patient [30]. SW48 colorectal cancer cells was derived from
a tumor at Duke’s C stage [30]. These five cell lines differ also in
FGFR4 protein expression levels [8]. In our study, no new SNPs
or activating mutations were found in FGFR4. However, loss-of-
function experiments revealed a major role of FGFR4 in
tumorigenic properties of colorectal cancer cells, since its depletion
abrogated proliferation, adhesion, migration and invasion.
FGFR4-silencing caused an up-regulation of E-cadherin expres-
sion and down-regulation of Snail and other epithelial-mesenchy-
mal transition (EMT) mediators. Finally, we demonstrated that
FGFR4 targeting was able to block tumor growth in vitro and
in vivo.
Materials and Methods
Ethics Statement
The Ethical Committee of the Consejo Superior de Investiga-
ciones Cientı´ficas (Madrid, Spain) approved the protocols used for
experimental work with mice.
Cell Lines, RNA Extraction, Antibodies and Inhibitors
Colorectal cancer cell lines KM12C and KM12SM [31,32]
were obtained from Dr I. Fidler (MD Anderson). SW480, SW48
and HEK293 cell lines were from ATCC. Cells were grown
according to established protocols [7]. RNA was extracted from
cell lines and 20 paired normal/tumoral tissue from cancer
patients with the RNeasy Mini Kit (Qiagen Inc.) according to the
manufacturer’s protocol. The extracted RNA was quantified with
a NanoDrop ND-1000 spectrophotometer (NanoDrop Technol-
ogies Inc.).
A total of 15 different antibodies were used, including proteins
related to the FGFR4 signaling pathway and control proteins.
Source, clonality, and conditions of usage for every case and
technique are specified in Table S1. FGFR4-specific polyclonal
antibody (sc-124, Santa Cruz Biotechnology) and control GST-
specific polyclonal antibody from GE Healthcare were used for
FGFR4-targeting experiments. FGFR inhibitors were PD173074
(Sigma) and TKI-258 (Novartis). PD173074 is a pan-FGFR
inhibitor that induces apoptosis [33]. TKI-258 is a clinically
relevant, multi-kinase inhibitor, including VEGFR and PDGFR
kinases among others [34]. Other inhibitors were: PP2 (Sigma) for
SRC, JNK Inhibitor II and UO126 (Calbiochem) for MEK1/2.
They were used at 3 mM and 15 mM as previously reported [35].
Vectors, shRNAs, siRNAs and Transfections
pRS vectors containing specific shRNAs (TI378641, TI378642,
TI378643 and TI378644) for FGFR4 (NM_022963) and a control
shRNA non-effective against any human sequence (TR30003)
were from Origene. Stably-transfected cells were obtained by
retroviral infection. Briefly, HEK293FT cells were transfected
with pRS vectors and pNGVL-gag-pol and pNGVL-VSVG
packaging vectors using jetPRIME Transfection Reagent (Poly-
plus). After incubating the cells for 12–15 h in serum-free media,
the media was replaced with DMEM containing 10% FBS and
penicillin/streptomycin. The day after, media containing lentiviral
particles was centrifuged, diluted 1:2–1:10 in DMEM containing
10% FBS and antibiotics and directly added to SW480 and SW48
colorectal cancer cells. After three days of incubation, infected
SW480 and SW48 colorectal cancer cells were selected using
1 mg/ml puromycin (Sigma) for 2–3 weeks. Then, cells were
cultured with 0.5 mg/ml puromycin.
FGFR4 siRNAs and controls were purchased from Sigma. For
siRNA transfections, 56105 cells were seeded in culture plates and
maintained in DMEM with 10% fetal calf serum at 37uC in 5%
CO2 for 24 h. Cells were transfected with 55 pmol siRNA using
2 ml JetPrime Transfection reagent in 200 ml of JetPrime buffer.
Then, 48 h after transfection, cells were analyzed by western blot
and semi-quantitative PCR [35].
Sequence Analysis, Semi-quantitative and Real-time
Quantitative PCR
cDNA was synthesized using the Superscript III First Strand
Synthesis kit (Invitrogen). The primers used to get the FGFR4
sequence were previously described [36]. Briefly, four pairs of
primers (A, B, C and D) were used to get the whole molecule by
PCR in fragments of approximately 1000 bp using the Advantage
2 polymerase (Clontech). Exonuclease I (USB) and shrimp alkaline
phosphatase (USB) were added to the PCR products. They were
directly sequenced in an ABI7002 sequencer (Applied Biosystems).
cDNA was synthesized as before and directly used for semi-
quantitative PCR analysis of TGF-b1 and GAPDH mRNA levels
in colorectal cancer cell lines. PCR reactions were performed
using the following primers; human TGF-b1, sense 59-AC-
CGGCCTTTCCTGCTTCTCA-39, antisense 59-
CGCCCGGGTTATGCTGGTTGT-39; human GAPDH, sense,
59-GGCTGAGAACGGGAAGCTTGT-39, antisense 59-
CGGCCATCACGCCACAGTTTC-39. Specific primers for
FGFR1-3 used to test the specificity of shRNAs and siRNAs
directed against FGFR4 were: FGFR1, sense 59-CACAAGC-
CACGGCGGACT-39, antisense 59-TGATGCTCCAGGTGG-
CAT-39; FGFR2, sense 59-CGTTGCCATTCAAGTGACTG-39,
Table 1. FGFR4 mutational status in colorectal cancer and
control cell lines.
Cell line properties Cell line Mutation
Non metastatic SW480 P136L
Highly-metastatic SW48 V10L
P136L
Low-metastatic KM12C V10L
P136L
G388R
Highly-metastatic KM12SM V10L
P136L
G388R
Pancreatic adenocarcinoma BxPc3 P136L
Human Embrionic Kidney HEK293 –
doi:10.1371/journal.pone.0063695.t001
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antisense 59- GACAAAATCTTCCGCACCATC-39; and
FGFR3, sense 59- CAGTTGGTCTTCGGCAGC-39, antisense
59-TGCTGCCAAACTTGTTCT-39.
For qRT-PCR, reactions were performed using previously
described EMT marker primers [37] and SYBR-Green Master
PCR mix (Applied Biosystems), in triplicate. PCR and data
collection were performed on IQ5 (BioRad). All quantitations
were normalized using human GAPDH. For the semi-quantitative
PCR, the D pair of primers was used to determine the amount of
FGFR4 cDNA, using GAPDH amplification with specific primers
as control [36].
Western Blot Analysis
Protein extracts from colorectal cancer cells were prepared and
quantified with the 2D-Quant kit (GE Healthcare) according to
previously published protocols [7]. Then, 25 mg of each protein
extract were run in parallel using 10% SDS-PAGE. For
immunoblotting, proteins were transferred to nitrocellulose
membranes (Hybond-C extra) using semi-dry equipment (Bio-
Rad). After blocking, membranes were incubated with specific
mono- or polyclonal antibodies against the selected proteins.
Membranes were incubated at optimized dilutions with primary
antibodies followed by incubation with either HRP-anti-mouse
IgG (Pierce) at 1:5000 dilution or HRP-anti-rabbit IgG (Sigma) at
1:5000 dilution. Specific reactive proteins were visualized with
SuperSignal West Pico Maximum Sensitivity Substrate (Pierce).
The abundance of the proteins in western blot assays was
determined by densitometry using Quantity One 1D Analysis
Software v4.6 (Bio-Rad Laboratories).
Cell Adhesion, Invasion, Apoptosis Detection,
Proliferation, and Wound Healing Assays
For cell adhesion assays, 96-well plates were coated with
Matrigel (0.4 mg/mm2) (BD Biosciences) in coating buffer (0.1 M
Figure 1. FGFR4-silencing in colorectal cancer cells decreases tumorigenic and invasive properties of colorectal cancer cells. Four
shRNAs directed against different exons of FGFR4 and a scrambled shRNA were used to obtain stably transfected colorectal cancer cells after
selection with puromycin. In addition, transient siRNA FGFR4-silencing was carried out in SW620 colorectal cancer cells. A. Western blot analysis of
FGFR4 expression in stably transfected SW480 and SW48 cell lines, and transiently-transfected SW620 cells. Tubulin was used as loading control. B.
Semi-quantitative PCR analysis of FGFR1, FGFR2, FGFR3, and FGFR4 expression using specific primers in three different cell lines. GAPDH was used as
control. C. Proliferation was determined by MTT assays after 24 h of culture. Optical density was significantly decreased by FGFR4 knockdown (*,
p,0.01; **, p,0.001). D. Scrambled and silenced cells were grown until confluence and their migratory capabilities were analyzed in a wound-healing
assay every 24 h until confluence. Representative images of the wound-healing assay are shown. Migration speed (mm/h) of scrambled and FGFR4-
silenced cells was calculated as the distance covered in 96 h. E. Cell adhesion to Matrigel of FGFR4-silenced or scrambled cells, after starving cells for
5 h in medium alone. F. SW480 and SW48 scrambled cells showed approximately 2-fold higher invasion than shRNA #41 FGFR4 stably-transfected
cells. Data for all the experiments represent the mean 6 SD of 3 independent experiments. p values of all the experiments are shown.
doi:10.1371/journal.pone.0063695.g001
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NaHCO3 pH: 8.8) overnight at 4uC and, then, incubated with
adhesion medium (0.5% bovine serum albumin in serum-free
DMEM) for 2 h at 37uC to block unspecific binding. Cells were
starved without serum for 5 h and labeled with BCECF-AM
(Molecular Probes) during 30 min at 37uC, detached with 2 mM
EDTA in PBS and resuspended in adhesion medium. Then, 105
cells were added in triplicate to plates and incubated for 30 min.
To remove non-adherent cells, plates were washed twice with
DMEM. Bound cells were lysed using 1% SDS in PBS and the
fluorescence quantified in a Varioskan Flash Multimode Reader
(Thermo Scientific). For Matrigel invasion assays, 86105 SW480
or SW48 cells were re-suspended in invasion medium (serum-free
DMEM containing 0.5% BSA) and loaded onto 8 mm pore-size
filters coated with 35–50 ml of 1:3 dilution of Matrigel (BD
Biosciences) in Transwells (Costar). The lower compartments of
invasion chambers were filled with medium containing 10% FBS
(Gibco). After 22 h of incubation at 37uC, non-invading cells were
removed from the upper surface of the filter, and cells that
migrated through the filter were fixed with 4% paraformaldehyde
(Sigma), stained with crystal violet and the invading cells counted
under a microscope. For wound healing, SW480 and SW48 cells
were seeded in triplicate at a density of 106 cells per well in 24-well
plates. After attachment, a 1 mm-wide wound was produced in the
cell monolayer, the growth medium was replaced and a picture
was taken (day 0) in an Olympus CK40 microscope equipped with
an Olympus DP12 camera at640 magnification. Pictures of the
same field were taken every 24 h.
For apoptosis detection assays, cells were incubated with 1 mM
H2O2 for 16 h without serum. Then, cells were detached and
incubated with FITC labeled-Annexin V (Miltenyi Biotec Inc.)
and propidium iodide according to manufacturer’s instructions,
and analyzed by cytofluorometry (Coulter Epics XL). For cell
proliferation assays, experiments were carried out following
established procedures [38,39]. Briefly, the growth medium was
Figure 2. Alterations in EMT inducers after FGFR4-silencing. A. cDNA synthesized from total RNA from stably and transiently-silenced and
control cells was subjected to qRT-PCR using specific primers for the EMT inducers SNAI1, TWIST1, ZEB1 and CDH1, using GAPDH for normalization.
Data represent the median 6 SD of two experiments. B. Same cDNA was subjected to semi-quantitative RT-PCR analysis to amplify TGFb1, using
GAPDH as control. C. SW480 and SW48 scrambled and FGFR4-silenced cells were lysed and subjected to WB analysis using specific antibodies against
the indicated proteins and EMT markers. The abundance of each protein was quantified by densitometry. Tubulin was used as loading control. D.
Immunofluorescence analysis of E-Cadherin in scrambled and silenced SW480 and SW48 cells. DAPI was used for counterstaining of the nucleus in
blue. E-Cadherin staining was in green.
doi:10.1371/journal.pone.0063695.g002
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changed 24 h after seeding (day 0) and cells were further
incubated during three days. Then, medium was removed and
cells were stained with 100 ml of the chromogenic dye 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (Sigma) at
a final concentration of 1 mg/ml in DMEM. The cells were
further incubated for 1 hr at 37uC and 5% CO2. Then, medium
was carefully aspirated and 100 ml of DMSO (Sigma) were added
to each well to disrupt cells. Absorbance was read at 570 nm. All
the experiments were done three times in duplicate. For reduction
of proliferation, cell viability was represented comparing the effect
of anti-FGFR4 or anti-GST (as control) antibodies or specific
inhibitors in comparison to untreated cells (100% of proliferation)
incubated in the same conditions [39].
Confocal Microscopy
Cells were fixed with 1% paraformaldehyde and permeabilised
with PBS-0.5% Triton X-100 prior to the incubation with the
FGFR4 specific antibody or TRITC-phalloidin for 1 h at 37uC.
FGFR4 or E-cadherin antibodies were detected with AlexaFluor
488-labeled anti-rabbit IgG antibody. Cells were observed with a
confocal microscope (TCS-SP5-AOBS-UV, Leica-Microsystems)
after nucleus counterstaining with DAPI. Images were acquired
with a 636 oil immersion objective using the Leica Confocal
Software. Displayed images were captured at the same sections in
the different samples.
In vivo Tumor Xenografts
Swiss nude mice (Charles River) were used for metastasis and
tumor xenograft studies. The Ethical Committee of the Consejo
Superior de Investigaciones Cientı´ficas (Madrid, Spain) approved
the protocols used for experimental work with mice.
For tumor xenografts, mice were injected subcutaneously into
the right flank using 16107 SW48 stably-transfected colorectal
cancer cells in 0.2 mL PBS in Matrigel diluted 1:3. Tumor sizes
were monitored at least twice a week and each animal was
euthanized using a CO2 chamber in accordance to the Guidelines
for Human Endpoints for Animal Use in Biomedical Research.
Statistical Analysis
All statistical analyses, except where indicated, were done with
Microsoft Excel. Data are presented as median 6 standard
deviation. For evaluation of the statistical significance compared
between groups all p values were derived from a two-tailed
statistical test with 95% confidence interval. p values ,0.05 were
considered statistically significant.
Results
FGFR4 Mutational Status in Colorectal Cancer Cell Lines
and Tissue Samples
We investigated FGFR4 mutations in colorectal cancer cell lines
and cancer samples that could contribute to antibody recognition
by overexpression or activation. Total RNA was isolated and
cDNA synthesized by retrotranscription. cDNA was used as
template to determine the presence of mutations.
In total, we found 3 SNPs in the FGFR4 cDNA in 4 colorectal
cancer cell lines and 20 cancer samples (Table 1 and Figure S1).
We observed three mutations in the extracellular and transmem-
brane domain of FGFR4 in patient samples. In addition to well-
characterized Arg388 SNP [9,15], we found V10L localized in the
signal peptide and P136L between immunoglobulin domains 1
and 2 (Figure S1). These two SNPs have been previously
reported without correlation to pathological manifestations
[40,41]. In KM12C and KM12SM colorectal cancer cells, we
observed the presence of the Arg388 SNP, whereas SW480 and
SW48 did not contain this SNP. In 20 colorectal cancer samples,
60% of patients presented the polymorphism Arg388, whereas the
prevalence of the other two mutations was 55% for P136L and
15% for V10L. These data are in agreement with previously
published data, where 50% of tumors present the Arg388 SNP,
53% the polymorphism P136L and 30% of the tumors contain
V10L [9].
We did not find any activating mutation in FGFR4 or any
nucleotide change out of previously reported for FGFR4. Then,
these data suggest that the increased expression of FGFR4 could
be responsible for autoantibody induction in CRC patients and
higher invasion and metastasis in colon cancer.
FGFR4 Knockdown Reduced Adhesion, Migration and
Invasion of Colorectal Cancer Cells
To study the role of FGFR4 overexpression in tumorigenesis
and metastasis, we studied the effect of FGFR4 expression in
SW48, SW480 and SW620 colorectal cancer cell lines, which did
not contain the Arg388 polymorphism. SW480 and SW48 cells
were stably transfected with four shRNAs targeting FGFR4 plus a
control scrambled shRNA. SW620 cells were transiently silenced
with siRNA. shRNA #41 showed the highest decrease in FGFR4
protein expression (Figure 1A) and mRNA levels (Figure 1B) in
both cell types. shRNA #44 was also effective in reducing protein
expression, particularly in SW48 cells. Similar reduction levels
were obtained with transient siRNA silencing in SW620 cells. To
study the effect of FGFR4 silencing on other family members, we
carried out RT-PCR. mRNA levels for FGFR1, FGFR2, and
FGFR3 remained unaltered after FGFR4- silencing, confirming
the specificity for FGFR4 (Fig. 1B). Immunofluorescence analysis
showed that FGFR4 expression was significantly reduced in
SW480 and SW48 after transfection with shRNA 41 vectors,
although some residual staining was observed in the nucleus of
SW48 cells (Figure S2).
To assess the tumorigenic properties, we determined cell
growth, adhesion, migration and invasion of FGFR4-silenced
cells. Using MTT assays, FGFR4-silenced SW480 or SW48 cells
showed a reduced proliferation rate when compared to scrambled
cells (Figure 1C). To investigate the effect of FGFR4 on
migration, FGFR4-silenced SW480 and SW48 cell lines were
seeded in 24-well plates and analyzed by wound healing assays.
FGFR4-silenced cells were unable to close the wound even after
96 h (Figure 1D). The retarded migration was more important
for SW48 (3-fold) than SW480 cells (2-fold). These results are
similar to those reported previously using two different CRC cell
lines, HCT116 and HT29, and different assays [15].
Figure 3. FGFR4 promotes proliferation and cell survival. A. Scrambled and FGFR4-silenced SW480 and SW48 cells were starved, and
incubated with FGF19, heparin, or FGF19 plus heparin for 30 min in DMEM. Then, cells were lysed and subjected to WB analysis using specific
antibodies against phosphorylated and total AKT, ERK1/2 and SRC. Tubulin was used as loading control. B. Cells were incubated in DMEM
supplemented with 10% FBS and antibiotics in presence or absence of H2O2 for 16 hours, and subjected to apoptosis detection assays. Unt.,
untreated cells. Data showed the results for one representative experiment out of three. C. Invasion across Matrigel of scrambled and silenced cells
treated with inhibitors to MEK1/2 (UO126), JNK, and SRC (PP2) as indicated. Data represent the mean 6 SD of 3 independent experiments.
doi:10.1371/journal.pone.0063695.g003
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Figure 4. Impact of FGFR4 targeting using kinase inhibitors on colorectal cancer growth. A. In vitro cell proliferation inhibition assays
were carried out using tyrosine kinase specific inhibitors. Experiments were performed in DMEM supplemented with 10% FBS and antibiotics. After
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In addition, using Matrigel assays, there was an important
decrease in the adhesion and invasion capacity of FGFR4-silenced
cells in both cell lines. SW480 cells decreased their adhesion
capacity in 2.5-fold, whereas SW48 cells showed almost 4-fold
reduction respect to scrambled cells (Figure 1E). Invasion was
approximately 2-fold reduced by FGFR4 knockdown in both cell
lines (Figure 1F). Collectively, these data support an important
role of FGFR4 in tumorigenesis and invasion of colorectal cancer,
being more relevant for metastatic SW48 cells.
FGFR4 Silencing Reduced the Expression of Inducers of
the Mesenchymal Phenotype
Since cell adhesion, migration and invasive capacity of epithelial
cells are associated to the epithelial-mesenchymal transition
(EMT), we decided to investigate alterations in EMT inducers.
After FGFR4 silencing, we studied changes in mRNA expression
levels of Snail1 (SNA1), TWIST1, ZEB1, and E-Cadherin (CDH1)
by real-time PCR or semi-quantitative PCR (TGFb1). In SW480
and SW620, FGFR4 knockdown caused a significant decrease in
EMT inducers TGFb1, SNA1 and TWIST accompanied by a
large increase in the epithelial marker CDH1 (Figure 2A, B).
SW48 cells exhibited a higher reduction in SNA1, TGFb1 and
TWIST1and a smaller increase in CDH1. ZEB1 decrease was
more significant in SW480 than in the metastatic cell lines SW620
and SW48. Epithelial and mesenchymal markers were analyzed at
the protein level by western blot. Snail and E-cadherin confirmed
mRNA results. Vimentin, a mesenchymal marker, was reduced
after FGFR4 silencing in the three cell lines (Figure 2C). Only
minor changes in MT1-MMP expression were detected in SW480
and SW48 cells after FGFR4-silencing. However, we observed a
large increase of MT1-MMP expression in SW620 cells, which
parallels the expression levels of E-cadherin indicative of a
reduction of the mesenchymal phenotype.
The increase in E-cadherin expression, after FGFR4 knock-
down, in adherens junctions and cell-cell contacts was confirmed
by immunofluorescence (Figure 2D). The differences in E-
cadherin expression were more evident in the cell membrane,
suggesting that FGFR4 silencing facilitated the expression of
functional E-cadherin on the cell surface and the reversion to an
epithelial phenotype. Collectively, these data using three different
colorectal cancer cell lines confirm that FGFR4 is an important
effector in EMT. FGFR4 knock-down provokes a reduction in
Snail and an increase in E-cadherin with the consequent effect on
adhesion, migration and invasion.
Signaling Analysis in FGFR4-silenced Cells. Role of FGFR4
in Cell Survival
To determine the effect of FGFR4 activity on downstream
signaling, we analyzed the effect of FGFR4-silencing on signaling
pathways after activation with FGF196 heparin compared with
serum-free medium. After FGFR4 knockdown, activation of
phosphoSRC, phosphoERK1/2 and phosphoAKT were signifi-
cantly lower in SW480 and SW48 (Figure 3A). ERK1 in
particular showed an almost complete reduction. Regarding AKT,
this effect suggests an effect mediated by FGFR4 through AKT on
EMT and cell survival. To test the effect of FGFR4 on survival,
cells were subjected to apoptosis induced by hydrogen peroxide.
FGFR4-silenced cells showed a significant decrease of 20–30% in
72 h of incubation with indicated concentrations, cell viability was determined by a MTT assay at 570 nm and represented as reduction of
proliferation (%). Absorbance of the untreated control cells was taken as 100% of cellular growth and the reduction of the cellular growth calculated
according to the following formula: (relative growth of untreated cells - relative growth of treated cells)/relative growth of untreated cells)6100. Each
column is the average of three independent experiments (each concentration tested in triplicate). Error bars indicate the standard deviation of the
assay. B. Targeting of FGFR4 using kinase inhibitors impairs downstream signaling pathways. Parental SW480 and SW48 cells were incubated with
indicated inhibitors at a concentration of 1.25 mM for 5 h, lysed with 0.5% SDS and subjected to western blot analysis using specific antibodies
against phosphorylated and total AKT, ERK1/2 and SRC. Tubulin was used as loading control.
doi:10.1371/journal.pone.0063695.g004
Figure 5. FGFR4-silencing reduces tumor growth in vivo. A. Scrambled and FGFR4-silenced SW48 cells were subcutaneously xenografted in
swiss nude mice and the growth of the tumors formed by each cell population was followed. The statistical significance for each time point was
determined by unpaired t-test. The comparison of the tumor volumes of the two mouse cohorts was statistically significant. B. Mice were visually and
manually inspected to determine the number of tumors implanted. Implanted tumors were as bar graph. C. At day 100, both groups of animals were
euthanized, and tumors were dissected and photographed. Dissected tumors representative for the both groups are depicted.
doi:10.1371/journal.pone.0063695.g005
FGFR4 Role in Colorectal Cancer
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survival in comparison to scrambled cells after hydrogen peroxide
treatment (Figure 3B). Without treatment, scrambled and
FGFR4-silenced SW480 and SW48 colorectal cancer cells showed
similar levels of apoptosis. This FGFR4 effect on cell apoptosis in
response to oxidative stress may play a role in advanced colorectal
cancer, facilitating the survival of metastatic colorectal cancer cells.
To study a synergistic effect to enhance FGFR4 inhibition on
signaling pathways in cell invasion, we used specific inhibitors on
targeted and scrambled cells. UO126 (a MEK1/2 inhibitor
upstream of ERK1/2) and PP2 (SRC inhibitor) reduced the
invasion capacity of SW480 and SW48 cells. This reduction was
much more pronounced in scrambled than in silenced cells
(Figure 3C). The JNK inhibitor caused only a minor effect on the
invasion capacity of scrambled and silenced SW480 and SW48
cells. Collectively, these results indicate that FGFR4-knockdown
caused a significant reduction of SRC and MEK1/2-ERK1/2-
mediated invasion in SW480 and SW48 cells, similar to that
caused by specific inhibitors on scrambled cells.
FGFR4 as Therapeutic Target in Colorectal Cancer
We followed two different strategies to prove the therapeutic
value of FGFR4 in colorectal cancer. First, we tested two kinase
inhibitors PD173074 and TKI-258. Then, we used FGFR4-
silenced cells to study the dependence on FGFR4 for tumor
growth in mouse xenografts. Metastatic cell lines (SW48 and
KM12SM), which express more FGFR4, were more sensitive to
chemical inhibitors than poorly or non-metastatic cell lines
(KM12C, SW480) (Figure 4A). Multi-kinase inhibitor TKI was
more effective than pan-FGFR inhibitor PD to reduce colorectal
cancer proliferation in a dose dependent manner (p value ,0.001),
particularly in metastatic cell lines. At 80 nM concentration,
inhibition was higher in metastatic colorectal cancer cell lines
(20% in SW48 and 60% in KM12SM) than in non-metastatic cells
or control cells. In KM12 cells, TKI inhibition was effective up to
1 nM concentration. Reference cell line HEK293, which expresses
low levels of FGFR4, was inhibited at a lower extent. Inhibition of
cellular growth was associated with inhibition of same downstream
regulators affected by FGFR4-signaling pathways (Figure 4B).
The most significant effects were obtained with TKI-258. We
observed a vast reduction (.90%) in SRC activation, a significant
decrease (50–80%) in phosphoERK1/2 and a weak reduction in
phosphoAKT in both cell lines (Figure 4B). The decrease in the
activation of FGFR4-signaling pathways was similar to that
observed after FGFR4-silencing, confirming the implication of
FGFR4. To confirm FGFR4 specificity, we used commercial anti-
FGFR4 antibodies on SW480 and SW48 colorectal cancer cells.
We observed a significant inhibition of the proliferation, dose-
dependent, in comparison to control cells (p value ,0.01) (Figure
S3). SW480 and SW48 colorectal cancer cell lines showed growth
inhibition after antibody treatment, up to 75% and 60% at
400 nM and 40% and 55% at 100 nM, respectively. Effect of anti-
FGFR4 antibody on control BxPc3 cells, not expressing FGFR4,
was marginal at 400 nM (18%) and negligible at 100 nM.
Finally, we injected scrambled and silenced SW480 and SW48
cells subcutaneously in nude mice to analyze the effect of FGFR4
silencing on tumor growth. Tumor development was significantly
slower in mice injected with FGFR4-silenced SW48 cells
(Figure 5A). By manual and visual inspection, we found that
scrambled SW48 cells were able to form tumors in $90% of
injected mice, whereas FGFR4-silenced SW48 cells formed tumors
in #60% of mice (Figure 5B). SW480 cells did not produce
tumors larger than 100 mm3 (data not shown). After tumor
resection, there was a clear difference in the vascularization and
the final tumor volume of the SW48-induced tumors (Figure 5C).
Scrambled cells produced large spherical tumors, whereas
FGFR4-silenced cells resulted in very small tumors. Moreover,
their whitish aspect suggested a deficiency in angiogenesis when
using silenced cells, as previously reported for FGFR1 and FGFR2
activity in glioma cells [42]. Collectively, targeting of FGFR4 with
different strategies showed a great potential of this receptor as
therapeutic target in colorectal cancer and a potential effect on
angiogenesis.
Discussion
FGFR targeting is becoming increasingly important for
therapeutic purposes in cancer [43,44,45]. Among FGF receptors,
FGFR1-3 have been considerably studied [46], whereas FGFR4
has been relatively less characterized at molecular level and for
therapeutic purposes. Previously, we demonstrated that autoanti-
bodies directed against FGFR4, in combination with other tumor-
associated antigens (TAAs), can be used as early diagnostic
markers of colorectal cancer [7,8,47]. Most of these TAAs were
kinases with significant mutational rate (i.e PIM1, SRC, MST1 or
ACVR2B among others). Although recurrent oncogenic somatic
mutations have been found in FGFR2 and FGFR3 [46], only the
SNP Arg388, present in .50% of the Caucasian ethnic group, was
described in FGFR4. This polymorphism has been associated to
poor prognosis and cancer aggressiveness in different cancers
[4,9,15]. Therefore, our first goal was to investigate the presence of
additional mutations in FGFR4. Sequence analysis showed the
presence of the Arg388 polymorphism in KM12C and KM12SM
colorectal cancer cells, but not in SW480, SW620 or SW48 cells.
Two additional SNPs were found in colorectal cancer cell lines
and patient samples, but no activating mutations were detected.
No correlation was found with progression or aggressiveness. In
contrast, FGFR4 in rhabdomyosarcoma showed activating muta-
tions in 7.5% of patients [17]. Our results suggest that FGFR4
overexpression appears to be a major determinant to influence
tumorigenesis and progression in colorectal cancer. Previous
reports that analyzed the relevance of Arg388 polymorphic alleles
of FGFR4 also required overexpression of FGFR4 [15].
In addition, we define a new role for FGFR4 as regulator of the
epithelial-mesenchymal transition and invasion in colorectal
cancer that makes it an attractive target for therapeutic
intervention. Our conclusions are based on the following
observations i) FGFR4 silencing caused a significant decrease in
proliferation, adhesion, migration and invasion in two different cell
lines, ii) pro-metastatic effects correlated with an important effect
on EMT mediators like Snail, Twist or E-cadherin. FGFR4
silencing by shRNAs and siRNAs caused a recovery of epithelial
markers like E-cadherin, iii) FGFR4 effects were mediated through
SRC, ERK and AKT pathways, with a significant effect on cell
survival, iv) silencing of FGFR4 almost abolished tumor growth in
mice xenografts, and v) small molecule inhibitors and FGFR4
targeting by specific antibodies diminished cell proliferation
in vitro. These results support the use of FGFR4 as therapeutic
target for colorectal cancer. As a side conclusion, we proved that
target proteins of cancer autoantibodies can be useful to identify
new therapeutic targets for cancer intervention.
The EMT process is fundamental for embryonic development
and involves profound phenotypic changes that include loss of cell-
cell adhesion, loss of cell polarity, and the acquisition of migratory
and invasive properties [48]. Association with EMT had been
described for FGFR1, -2 and -3 [49,50,51,52], but there were no
previous data for FGFR4 implication. Particularly little was known
about the relationship between FGFR activity and the transcrip-
tion factors SNAIL, TWIST and ZEB1 that regulate EMT. We
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demonstrated that FGFR4 suppression reduces significantly the
levels of TWIST in colon cancer cells, more than those of SNAIL.
ZEB1 was the less affected by FGFR4 silencing. ZEB1 targets
miR200 and basement proteins and seems to be more implicated
in final steps of metastasis. In summary, suppression of FGFR4
expression in colorectal cancer cells produced a reversion of the
mesenchymal to a more epithelial phenotype and the reduction of
tumorigenic properties of colorectal cancer cells. FGFR4 regulates
both the expression and the stability of TGFb, SNAIL and
TWIST genes as well as the MAPK (proliferation) and AKT
(survival) pathways [25].
The relevance of FGFR4 as therapeutic target in CRC was
demonstrated with multikinase inhibitors and specific antibodies,
as previously done for other FGFRs [33,44,53]. In our hands, the
promiscuous kinase inhibitor TKI-258 was much more efficient
than the more selective FGFR inhibitor PD173074. It was also
remarkable that KM12 cells, which contained FGFR4 Arg388
mutation, were extremely sensitive to TKI-258. Remarkably,
drugging FGFR4 by specific inhibitors produced a reduction of
key molecules of the FGFR4 signaling pathway (SRC and ERK1/
2) at the same extent than FGFR4-silenced cells. This similarity of
action points out that FGFR4 should be a critical target in these
cells. The use of specific antibodies for FGFR4 inhibition also
showed a neutralizing effect on colon cancer cells that confirmed
the specificity of the inhibition. Indeed, in a recent report, it has
been described that targeting FGFR4 with an specific monoclonal
antibody inhibited hepatocellular carcinoma growth in a mouse
xenograft model [54]. Together, these results indicate that
targeting of FGFR4 might become a potent therapeutic tool in
colon cancer.
In summary, we have demonstrated a potent oncogenic activity
of FGFR4 in colon cancer cells. Its effect on cell migration and
invasion were related to a clear regulation of EMT mediators like
SNAIL, Twist or E-cadherin. The results obtained with different
approaches for FGFR4 blocking indicate the efficacy of FGFR4-
targeting as therapeutic alternative for colorectal cancer. It might
be applied also to other cancers with high FGFR4 expression
levels. We believe our findings could have direct translation into
clinic by using FGFR4-based therapies.
Supporting Information
Figure S1 FGFR4 mutational status of the CRC cell lines used
in the study. A. Location of the FGFR4 mutations observed in the
colorectal cancer cell lines used in this study. Protein domain
boundaries were defined by the results of a search of the NCBI
Conserved Domain database (NCBI CD-Search). Red, signal
peptide; blue, transmembrane domain. IG, immunoglobulin-like
domain; S, disulfide bond. B. Mutational status of SW480 cells. C.
Mutational status of SW48 cells. D. Mutational status of KM12C
cells. E. Mutational status of KM12SM cells.
(PPTX)
Figure S2 Analysis of the expression of FGFR4 by confocal
microscopy with stably-transfected SW480 and SW48 cells. DAPI
was used to detect the nucleus of the cells in blue. Representative
micrographs show FGFR4 in green and F-actin (TRITC-
phalloidin) in red.
(PPTX)
Figure S3 FGFR4 targeting using anti-FGFR4 antibodies on
colorectal cancer growth. In vitro cell proliferation inhibition assay
using FGFR4 specific antibody or an antibody against GST as
control. Experiments were performed in DMEM supplemented
with 10% FBS and antibiotics. After 72 h of incubation with
indicated concentrations, cell viability was determined by a MTT
assay at 570 nm and represented as reduction of proliferation (%).
Absorbance of the untreated control cells was taken as 100% of
cellular growth and the reduction of the cellular growth calculated
according to the following formula: (relative growth of untreated
cells - relative growth of treated cells)/relative growth of untreated
cells)6100. Each column is the average of three independent
experiments (each concentration tested in triplicate). Error bars
indicate the standard deviation of the assay.
(PPTX)
Table S1.
(XLS)
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